InsiderClue
← All stocks

Protagonist Therapeutics, Inc

PTGX Net selling
CIK 0001377121 #955 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$80.64M
$257.00K on a plan · $73.43M straight out of an exercise
Sold at will
$6.94M
8 of 37 sales
Net
−$80.64M
−$6.94M against sales at will

By person

9 insiders · 38 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
PATEL DINESH V PH D
President and CEO
—
$53.07M (13) scheduled
−$53.07M
522,968
0.8082%
$75.36M
+1.4%
Ali Asif
Chief Financial Officer
—
$7.32M (5) scheduled
−$7.32M
59,003
0.0912%
$8.50M
+64.6%
Giraudo Bryan
Director
—
$5.92M (4) scheduled
−$5.92M
12,695
0.0196%
$1.83M
−54.7%
Waddill William D.
Director
—
$5.84M (7) scheduled
−$5.84M
7,825
0.0121%
$1.13M
−34.8%
MOLINA ARTURO MD
Chief Medical Officer
—
$4.49M (6) scheduled
−$4.49M
84,115
0.1300%
$12.12M
+74.0%
SELICK HAROLD E
Director
—
$2.52M (1) scheduled
−$2.52M
60,845
0.0940%
$8.77M
+117.3%
Williams Lewis T
Director
—
$1.48M (1) scheduled
−$1.48M
7,825
0.0121%
$1.13M
—
Gupta Suneel
Chief Development Officer
—
—
—
267,433
0.4133%
$38.54M
+44.9%
O'Dowd Sarah A
Director
—
—
—
7,825
0.0121%
$1.13M
—

Individual transactions

8
Insider
Date
Role
Action
Shares
Price
Amount
Giraudo Bryan
8 May 2026
Director
Sell
5,130
$100.00
$513.00K
Giraudo Bryan
8 May 2026
Director
Sell indirect
6,000
$100.00
$600.00K
Ali Asif
20 Apr 2026
Chief Financial Officer
Sell
1,750
$105.47
$184.57K
MOLINA ARTURO MD
23 Jan 2026
Chief Medical Officer
Sell
13,151
$82.42
$1.08M
Ali Asif
20 Jan 2026
Chief Financial Officer
Sell
8,588
$82.48
$708.34K
PATEL DINESH V PH D
20 Jan 2026
President and CEO
Sell
34,438
$82.48
$2.84M
MOLINA ARTURO MD
20 Jan 2026
Chief Medical Officer
Sell
9,514
$82.48
$784.71K
MOLINA ARTURO MD
17 Nov 2025
Chief Medical Officer
Sell
2,712
$84.77
$229.90K
Show all 38 transactions →

What was left out

Form 4 filings counted 36
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 1
Sales straight out of an exercise 28
Sales at will 8
Transactions with no price 0
Shares from compensation/vesting 850,522
History held since 15 Sep 2016